This article reviews the role of emerging biologic drugs for the treatment of rheumatoid arthritis (RA). Besides anti-tumor necrosis factor (TNF)-alpha and anti-interleukin (IL)-1 agents (Infliximab, Adalimurnab, Etanercept and Anakinra) whose clinical efficacy is now established, new drugs have been proposed for the therapy of rheumatoid...
-
2005 (v1)PublicationUploaded on: December 2, 2022
-
1995 (v1)Publication
No description
Uploaded on: April 14, 2023 -
1997 (v1)Publication
No description
Uploaded on: April 14, 2023 -
1994 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2001 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Antiphospholipid antibody syndrome (APS) is an autoimmune acquired thrombophilia characterized by recurrent thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). APS can be primary, if it occurs in the absence of any underlying disease, or secondary, if it is associated with another autoimmune disorder, most...
Uploaded on: April 14, 2023 -
2006 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2000 (v1)Publication
No description
Uploaded on: October 11, 2023 -
1982 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
Rheumatoid arthritis (RA) is a chronic inflammatory immune-mediated systemic disease which primarily affects the joints. Leflunomide (LFN) is a disease modifying anti-rheumatic drugs (DMARDs) which acts by inhibiting the synthesis of pyrimidines. Several trials have demonstrated the efficacy and safety of LFN alone or in combination with...
Uploaded on: April 14, 2023 -
1980 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2014 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2003 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2012 (v1)Publication
Lymphedema is a chronic, progressive, and often debilitating condition. Primary lymphedema is a lymphatic malformation developing during the later stage of lymphangiogenesis. Secondary lymphedema is the result of obstruction or disruption of the lymphatic system, which can occur as a consequence of tumors, surgery, trauma, infection,...
Uploaded on: April 14, 2023 -
2000 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2010 (v1)Publication
BACKGROUND: The problem of prevention of lymphatic injuries in surgery is extremely important if we think about the frequency of both early complications such as lymphorrhea, lymphocele, wound dehiscence, and infections and late complications such as lymphangites and lymphedema. Nowadays, it is possible to identify risk patients and prevent...
Uploaded on: March 31, 2023 -
1995 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Cilostazol is a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating properties. The aim of our study was to evaluate the effect of the drug on vasculopathy and Raynaud's phenomenon (RP), in a series of patients with systemic sclerosis (SSc), before and after cilostazol treatment. Twenty-one...
Uploaded on: March 27, 2023 -
1995 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2003 (v1)Publication
There is convincing evidence that soluble HLA-A,-B,-C (sHLA-A,-B,-C) and soluble HLA-G (sHLA-G) antigens can induce apoptosis in CD8(+) activated T cells although there is scanty and conflicting information about the mechanism(s) by which sHLA-A,-B,-C antigens and sHLA-G antigens induce apoptosis. In this study we have compared the...
Uploaded on: April 14, 2023 -
2008 (v1)Publication
Recurrent intestinal perforation associated with thrombosis of inferior vena cava: uncommon presentation of antiphospholipid syndrome.
Uploaded on: April 14, 2023 -
2009 (v1)Publication
No description
Uploaded on: April 14, 2023